Log In
Print
BCIQ
Print
Print this Print this
 

AFM13

  Manage Alerts
Collapse Summary General Information
Company Affimed Therapeutics N.V.
DescriptionTetravalent bispecific human antibody targeting CD30 and Fc gamma receptor IIIa (CD16a; FCGR3A; FcgammaRIIIa)
Molecular Target CD30 ; Fc gamma receptor IIIa (CD16a) (FCGR3A) (FcgammaRIIIa)
Mechanism of ActionBinds CD30; Binds CD16; Antibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I/II
Standard IndicationHodgkin's disease
Indication DetailsTreat Hodgkin's disease; Treat Hodgkin's lymphoma
Regulatory Designation

U.S. - Orphan Drug (Treat Hodgkin's lymphoma);
EU - Orphan Drug (Treat Hodgkin's lymphoma)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today